CP-532623

CP-532623 is a CETP inhibitor and elevates high-density lipoprotein cholesterolion. CP-532623 is a close structural analogue of Torcetrapib. CP-532623 has highly lipophilic properties[1][2][3].

Product Specifications

CAS Number

[261947-38-0]

UNSPSC

12352005

Hazard Statement

H302

Target

CETP

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/cp-532623.html

Purity

99.0

Solubility

DMSO : 20 mg/mL (ultrasonic; warming)

Smiles

O=C(N1[C@H](CC)C[C@H](N(C(C)=O)CC2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2)C3=C1C=CC(C(F)(F)F)=C3)OC(C)C

Molecular Formula

C27H27F9N2O3

Molecular Weight

598.50

Precautions

H302

References & Citations

[1]Blasi E, et al. Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure. J Cardiovasc Pharmacol. 2009 Jun;53 (6) :507-16.|[2]Trevaskis NL, et al. The mechanism of lymphatic access of two cholesteryl ester transfer protein inhibitors (CP524,515 and CP532,623) and evaluation of their impact on lymph lipoprotein profiles. Pharm Res. 2010 Sep;27 (9) :1949-64.|[3]Trevaskis NL, et al. The role of the intestinal lymphatics in the absorption of two highly lipophilic cholesterol ester transfer protein inhibitors (CP524,515 and CP532,623) . Pharm Res. 2010 May;27 (5) :878-93.